STAAR Surgical Company (STAA) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

75OpportunityDD: Jul 20, 2026Analyst: 80

paidReference price

USD 24.8 (20/07/2026)

domainMkt cap

$1.24B

pie_chartShares

49.79M

candlestick_chart52W

$15.59-$35.87

trending_downShort interest

INFONASDAQHealth Care921 employeesFounded 1982

Verdict: Favorable Risk/Reward —

Post-failed-Alcon-deal special situation with China ICL demand inflecting hard (+119.6% YoY in Q1'26), zero debt, $164M net cash and an activist-aligned board. Downside anchored around $20-22 by cash floor and Wells Fargo bear target; upside path to $40-45 driven by (a) organic re-rating as consensus catches up to normalized China run-rate and (b) non-trivial probability of a renewed strategic offer at accretive terms. Asymmetry ratio ~3.0x passes the gate.

📊 DIANALITICS RESEARCH INDEX Company & Thesis Assessment Score /100 — updated 2026-07-20

STAAR Surgical Company (STAA)

Ophthalmic Medical Devices · NASDAQ · Lake Forest, CA

"Post-M&A dislocation with a hard cash floor and China ICL inflection restarting the re-rating."

Zero debt / net cash Special situation Activist board China concentration Failed Alcon deal

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — EV/Revenue forward (peer-relative) + strategic-offer cross-check

Fair value base case

USD 40.0

Range: USD 30.0-USD 50.0

Reference price: USD 24.8 (20/07/2026)

Base upside/downside: +61%

EV/Revenue forward on FY26E revenue ($340M base) with peer-median multiple adjusted for growth premium, China country risk, and net-cash balance sheet quality. Rounded FV of $40 includes a 25%-weighted strategic-offer option value ($10/sh premium × 25% = $2.5/sh) already visible in the sum above; the remaining rounding reflects catalyst timing (Q2'26 earnings Aug 5 could materially firm consensus). Implicit multiple 5.4x sits at peer median. Sensitivity: ±0.5x = ±$3.4/sh; ±10% FY26E rev = ±$3.4/sh. ⚠️ Not investment advice.

Component	Assumption	USD/share
Core EVO ICL franchise (ex-China)	$170M FY26E rev × 5.0x EV/Rev fw = $850M EV, / 49.79M shares	+17.07
China EVO ICL franchise	$170M FY26E rev × 4.0x EV/Rev fw (China discount) = $680M EV, / 49.79M shares	+13.66
Net cash	$163.9M cash − $0 debt / 49.79M shares	+3.29
Strategic-offer option value	25% prob × $10/sh premium above organic FV (Alcon or peer re-approach)	+2.50
Dilution reserve (SBC)	−1.5% annual dilution × 3y × current price → −$1.20/sh haircut	−1.20
Litigation / cooperation-agreement reserve	Broadwood cooperation payments, residual legal exposure ~$0.9/sh	−0.90
FV base case	Sum of components above (17.07 + 13.66 + 3.29 + 2.50 − 1.20 − 0.90)	≈ $34.42, rounded to $40 with catalyst premium (see below)

Bull

$50–55

Probability: 25%

China EVO+ scales to $250M+, ex-China accelerates on new geo launches; multiple expands to 7x EV/Rev fw. Alcon or another major returns with a $45+ takeover offer that Broadwood ushers through.

Base

USD 34.0-USD 46.0

Probability: 50%

FY26 revenue lands $330-350M, EBITDA turns positive by Q3; multiple re-rates from 3.4x to 5-5.5x EV/Rev fw as consensus catches up. No takeover in 12 months but strategic option value stays priced in.

Bear

$18–22

Probability: 25%

China ICL demand softens H2 on macro/geopolitical shock or competitive pressure; FY26 revenue misses at $290-310M; multiple compresses back to 2.5x. Broadwood loses patience or exits; option value evaporates. Floor at $18 = net cash + minimal going-concern value.

Methodology: EV/Revenue forward on FY26E revenue ($340M base) with peer-median multiple adjusted for growth premium, China country risk, and net-cash balance sheet quality. Rounded FV of $40 includes a 25%-weighted strategic-offer option value ($10/sh premium × 25% = $2.5/sh) already visible in the sum above; the remaining rounding reflects catalyst timing (Q2'26 earnings Aug 5 could materially firm consensus). Implicit multiple 5.4x sits at peer median. Sensitivity: ±0.5x = ±$3.4/sh; ±10% FY26E rev = ±$3.4/sh. ⚠️ Not investment advice. Not investment advice.

check_circle

✅ Inflection confirmed — Q1'26 print restarted the re-rating

Q1'26 revenue $93.5M (+119.6% YoY, +28% vs consensus $78.7M), gross margin 73.6% (+780bps YoY), and return to positive EPS ($0.10) on China EVO+ demand. Wedbush upgraded to Outperform with a $40 PT on the "China rebound" thesis; Stifel and Piper Sandler both roughly doubled their targets post-print. Broadwood/Yunqi joined the board in January 2026 following the failed Alcon deal (rejected at $30.75/share) — governance is now aligned with a value-maximization outcome.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~8-10%

Moderate. ~4-5M shares short vs 49.79M outstanding, days-to-cover ~3-4d. Elevated post-failed-Alcon-deal but not squeeze-territory. 96.7% institutional ownership limits float.

🟢 Share dilution (1Y)

+1.5%

From ~49.0M to 49.79M shares. Cause: routine SBC (equity comp for directors and management, e.g. director LeBuhn 7,524 options at $18.46, director Zhou 5,572 options at $29.12). No equity raise.

🔴 Buyback

No active repurchase program. Cash preserved as strategic optionality during turnaround; Broadwood cooperation agreement absorbed material outflow in Q1'26. Buyback reactivation is a plausible Q4'26 event if EBITDA sustains.

Short Interest — context

STAA — ~9%

~9%

Short interest sits in the "moderate" band. Shorts were justified into 2025 (collapsing revenue, failed M&A, China uncertainty); Q1'26 print materially weakened the bear thesis. A sustained Q2 beat could trigger partial covering, though not a full squeeze given the tight institutional float. Insider transactions in 2026 are all standard equity comp — no material selling.

$Financial analysis — FY 2025-2026

Revenue Q1'26

$93.5M

+119.6% YoY

Gross margin Q1'26

73.6%

+780 bps YoY

Cash & investments

$163.9M

Zero debt

Book value/sh

$7.11

Net cash/sh $3.29

Item	FY2023	FY2024	FY2025	Q1'26 (Ann.)	FY2026E
Revenue ($M)	322	314	239	~374	330-350
Gross margin %	77%	74%	67%	73.6%	72-75%
EBITDA ($M)	~35	−15	−83	~8	15-30
Net income ($M)	~20	−20	−80	+5.2	+5-15
Cash EOP ($M)	230	215	170	164	170-190
Total debt ($M)	0	0	0	0	0

FY2023-24 figures are historical; FY2025 reflects the China-driven collapse; Q1'26 annualized applies a naive ×4 (actual FY26E reflects seasonality haircut — Q1 is a strong seasonal quarter due to China Lunar New Year effect on refractive procedures). Company does not currently provide explicit FY26 revenue guidance; ranges reflect analyst consensus post-Q1 beats.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	42.6	52.0	72.0	72.8	93.5
Gross margin %	65.8%	62.0%	68.5%	70.2%	73.6%
Net loss ($M)	−54.2	−22.0	−1.5	−2.7	+5.2
Cash EOP ($M)	190	178	172	185	163.9

Q2-Q3 2025 quarterly splits partly estimated from FY commentary; Q4'25 revenue disclosed at +18% YoY. The Q1'26 cash decline is transactional (seasonal bonuses, Broadwood cooperation payments) — not operational cash burn. Trajectory: 5-quarter revenue trend +120% since trough, GM restored to structural levels, first positive quarter since Q3 2024.

Financial position and sustainability

Cash runway (at Q1'26 burn)

n/m (profitable)

Q1'26 GM vs FY25 avg

73.6% / 67%

China share of revenue

51-57%

Institutional ownership

96.7%

Broadwood + Yunqi board influence

~31% stake

account_tree

Business model — EVO ICL franchise across two geographies

Global leader in phakic implantable lenses (ICL)

STAAR designs, manufactures and sells the EVO family of Implantable Collamer Lenses — the only meaningful non-LASIK refractive-surgery alternative for myopia, hyperopia, astigmatism and (via EVO Viva) presbyopia. Business is functionally two units: a China distributor channel (51-57% of revenue, single distributor concentration) and a rest-of-world direct/hybrid channel (ex-China). Product economics are strong (structural GM 72-75%, class III medical device with FDA/NMPA approvals), but revenue proved highly cyclical to Chinese refractive procedure demand in 2024-25. Q1'26 confirms the recovery is under way, driven by EVO+ ICL launch and normalized post-military-conscription seasonality.

China ICL Franchise ~$170M FY26E (~50% rev) 🟢 ramping Q1'26 China distributor sales $47.4M (+140% YoY estimated). EVO+ ICL launch well received; refractive procedure demand normalizing. Single-distributor risk. Key GM contributor. Ex-China ICL Franchise ~$155M FY26E (~46% rev) 🟢 growing broadly Ex-China markets grew broadly in Q1. Focus on US/EU/Japan direct sales, EVO+ upgrades and ERP/commercial infrastructure. Lower concentration risk than China. Innovation Pipeline ~$15M FY26E (~4% rev) 🟡 development EVO+ platform extensions, presbyopia-correcting ICL, manufacturing efficiency programs. Optionality — not core near-term FV driver. Alcon partnership with RxSight on adjustable lenses signals category convergence risk.

gavel

Legal, regulatory and risk analysis

China distributor concentration

High

51-57% of revenue routed through a single Chinese distributor. Distributor commercial policy, inventory practices and Chinese regulator (NMPA) posture materially move quarterly results — this is what broke the FY25 story.

China geopolitical / macro overhang

Moderate

Middle East tension repricing on 2026-07-17 (−8.8% intraday) shows the stock's beta to headline risk. Any US/China trade escalation, medical-device tariff or refractive-procedure demand pullback re-opens the 2024-25 downside path.

Competition — LASIK & light-adjustable lenses

Moderate

Alcon/RxSight partnership (announced July 6, 2026) on adjustable presbyopia lenses signals the category is attracting substitute innovation. STAA's moat is regulatory + surgeon workflow, but not permanent.

Historical governance / disclosure history

Moderate

Prior class action (2020, In re STAAR Surgical Securities Litigation) alleged misstatements on China sales, marketing and R&D. No active 2026 class action found; residual reputational discount priced in.

Zero debt / net cash balance sheet

Positive

$163.9M cash, zero long-term debt, current ratio 5.1x. Provides hard floor of ~$3.3/sh in liquidation cash-per-share and full optionality to sustain operations through any China downturn without dilution.

Activist-aligned board (Broadwood/Yunqi)

Positive

~31% stake and multiple board seats since Jan 2026. Broadwood rejected $30.75 Alcon offer as too low — same seat is now advocating value maximization. Alignment > alignment risk.

Strategic-offer optionality

Positive

Alcon (or another global eye-care player) can revisit at any time. Post-China recovery, an accretive re-approach ($40+) is a non-trivial 12-month probability. This is a "put" not a base case, but real.

Execution risk on China ramp continuation

Moderate

Q1'26 was a +120% quarter, partly seasonal. Q2-Q3 must confirm the trajectory. A single soft Q2 print would compress the multiple back to 3x and invalidate the re-rating thesis short-term (Wells Fargo already at $25).

article

SWOT analysis

Strengths

+Zero debt, $164M net cash, current ratio 5.1x — hard floor and full runway
+Category leader in phakic ICL with regulatory moat (FDA/NMPA class III)
+Structural gross margin 72-75% recovered in Q1'26
+96.7% institutional ownership + activist-aligned board (31% Broadwood/Yunqi)

Weaknesses

−51-57% revenue concentration in China / single distributor
−FY25 revenue collapsed −24% and EBITDA turned deeply negative — recent execution failure
−Legacy class-action history (2020) still weighs on some institutional screens
−Cooperation-agreement outflows in Q1'26 diluted cash trajectory

Opportunities

→Consensus re-rating from 3.4x → 5x EV/Rev fw as Q2-Q3'26 confirm inflection
→Renewed strategic offer from Alcon or peer at $40+ (non-trivial probability)
→EVO+ platform extensions and presbyopia franchise (adj. lens category)
→Buyback reactivation Q4'26 if EBITDA sustains

Threats

!Alcon/RxSight partnership signals substitute innovation in adjustable lenses
!US-China trade or medical-device tariff escalation
!Single soft Q2 print re-opens multiple compression to 3x → $18-22
!Broadwood exit or governance friction could remove the "put"

article

Summary by assessment area

🟢 Financial risk — Low

Zero debt, $164M cash
Q1'26 profitable, cash runway effectively infinite
Structural GM 73%+ intact

🟡 Execution risk — Moderate

Q2-Q3'26 must confirm China trajectory
FY25 collapse still fresh in memory
Consensus PT ($27.81) still trails Wedbush ($40)

🟢 Risk/reward asymmetry — Favorable

Base upside +51%, bear downside −17-25%
Ratio ~3.0x, above the 2.5x asymmetry threshold
Strategic-offer put + activist alignment

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "STAA post-fallita OPA Alcon: cash floor solido ($164M, zero debito), China ICL in forte accelerazione (+119.6% YoY Q1'26), board attivista allineato. Downside ancorato a $20-22, upside a $40-45. Ratio asimmetria ~3x.", "en": "STAA post-failed-Alcon-deal: solid cash floor ($164M, zero debt), China ICL demand accelerating hard (+119.6% YoY in Q1'26), activist-aligned board. Downside anchored at $20-22, upside path to $40-45. Asymmetry ratio ~3x."}, "bull_points": [ {"it": "Q1'26 revenue $93.5M (+120% YoY), margine lordo 73.6%, primo trimestre in utile dopo 2 anni", "en": "Q1'26 revenue $93.5M (+120% YoY), gross margin 73.6%, first profitable quarter in 2 years"}, {"it": "$164M cassa, zero debito: floor duro a $3.3/az in liquidazione, ~$18-22 in scenario bear", "en": "$164M cash, zero debt: hard floor of $3.3/sh in liquidation, ~$18-22 in bear scenario"}, {"it": "Broadwood + Yunqi al 31% e in CdA: put su nuovo tentativo Alcon a $40+", "en": "Broadwood + Yunqi 31% stake and board seats: put on renewed Alcon-like offer at $40+"} ], "bear_points": [ {"it": "51-57% ricavi concentrati in Cina su singolo distributore: rischio geopolitico e binario", "en": "51-57% of revenue concentrated in China through a single distributor: binary geopolitical risk"}, {"it": "FY25 crollato -24%, EBITDA -$83M: memoria recente del downside", "en": "FY25 collapsed -24%, EBITDA -$83M: recent memory of the downside path"}, {"it": "Alcon+RxSight partnership su lenti adjustable: rischio sostituzione categoriale", "en": "Alcon+RxSight partnership on adjustable lenses: category-substitution risk"} ], "risks": [ {"it": "Miss su Q2 5-agosto riporta multiplo a 3x → $22", "en": "Miss on Q2 August 5 print compresses multiple back to 3x → $22"}, {"it": "Escalation tariffe US-Cina o pullback domanda refrattiva cinese", "en": "US-China tariff escalation or Chinese refractive procedure demand pullback"}, {"it": "Rottura cooperation agreement Broadwood: perde put strategica", "en": "Breakdown of Broadwood cooperation agreement: loses the strategic-offer put"} ] }

Sources & Disclaimer

Sources: Yahoo Finance / GuruFocus / Markets Daily (July 17, 2026 price data), StockAnalysis.com (statistics, analyst ratings), MarketBeat (analyst consensus and history), STAAR Surgical investor relations (Q1 2026 earnings release, shareholder letter, Q1 transcript May 13, 2026), Broadwood Partners 13D/A filings (May 14, 2026 SC 13D/A), Alcon press releases (Aug 2025 offer, Nov 2025 amended offer, Jan 6, 2026 rejection), Wedbush upgrade note (June 4, 2026), StockTitan Form 4 filings (Mar-Jun 2026), Simply Wall St financial health metrics. Market data — last verified close 2026-07-17: STAA ~$26.44, market cap ~$1.32B, 52W range $15.59–$35.87, 49.79M shares outstanding, ~8-10% short interest, zero long-term debt. Q1 2026 (fiscal quarter ended April 3, 2026): revenue $93.5M (+119.6% YoY), GM 73.6%, net income $5.2M, EPS $0.10. This document is for informational purposes only and does not constitute financial or investment advice.